AV Medical Introduces Chameleon PTA Balloon Catheter in the United States

 

July 18, 2016—AV Medical Technologies Ltd. announced today that it has commenced cases in the United States as part of its limited launch of the Chameleon angioplasty balloon catheter. The Chameleon is targeted for dialysis patients undergoing routine angioplasty procedures. Israel-based AV Medical announced US Food and Drug Administration clearance for the device in October 2015.

With AV Medical’s SuperVision design, the Chameleon provides simultaneous balloon inflation and injection of fluids in one device. The device allows physician to visualize by injecting contrast through the catheter, whether the balloon is inflated or deflated, all while maintaining wire position.

In AV Medical’s press release, Jeffrey Hoggard, MD, commented, “The Chameleon balloon brings a number of unique advantages to dialysis access cases. Combining diagnostic imaging and balloon angioplasty in one device simplifies many procedures. I am able to eliminate a number of device exchanges compared to standard balloons. The unique Chameleon design allows me to maintain wire access throughout the entire procedure. This provides an improved level of efficiency and confidence during the procedure.” Dr. Hoggard is an interventional nephrologist with Capitol Nephrology Associates in Raleigh, North Carolina.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.